These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31949703)

  • 1. Atractyloside mimics
    Fang M; Song Y; Ren J; Yuan H; Fang J; Yan D; Zhang Y; Wang X
    Int J Clin Exp Pathol; 2018; 11(7):3286-3293. PubMed ID: 31949703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brother of Regulator of Imprinted Sites (BORIS) suppresses apoptosis in colorectal cancer.
    Zhang Y; Fang M; Song Y; Ren J; Fang J; Wang X
    Sci Rep; 2017 Jan; 7():40786. PubMed ID: 28098226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atractyloside inhibits gefitinib‑resistant non‑small‑cell lung cancer cell proliferation.
    Yao W; Liu C; Zhang N; Zhang Y; Qian Y
    Oncol Lett; 2024 Oct; 28(4):466. PubMed ID: 39119229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brother of regulator of imprinted sites inhibits cisplatin-induced DNA damage in non-small cell lung cancer.
    Zhang Y; Song Y; Li C; Ren J; Fang M; Fang J; Wang X
    Oncol Lett; 2020 Nov; 20(5):251. PubMed ID: 32994814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [BORIS Regulates SOCS3 Expression Through Epigenetic Mechanisms in Human Hepatocellular Carcinoma Cells].
    He JY; Liu QY; Wei L; Liu ZJ; Huang Y; Yu XQ; Li B; Qin Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 49(1):1-7. PubMed ID: 29737080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
    Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
    Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BTApep-TAT peptide inhibits ADP-ribosylation of BORIS to induce DNA damage in cancer.
    Zhang Y; Fang M; Li S; Xu H; Ren J; Tu L; Zuo B; Yao W; Liang G
    Mol Cancer; 2022 Aug; 21(1):158. PubMed ID: 35918747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CMap analysis identifies Atractyloside as a potential drug candidate for type 2 diabetes based on integration of metabolomics and transcriptomics.
    Li H; Shi X; Jiang H; Kang J; Yu M; Li Q; Yu K; Chen Z; Pan H; Chen W
    J Cell Mol Med; 2020 Jul; 24(13):7417-7426. PubMed ID: 32469143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the brother of the regulator of imprinted sites gene in the sputum of patients with lung cancer.
    Lee HY; Kim JI; Cho SH; Ko TY; Kim HS; Park SD; Cho SR; Chang HK; Hwang GJ; Jung SB
    Korean J Thorac Cardiovasc Surg; 2014 Aug; 47(4):378-83. PubMed ID: 25207247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
    Alberti L; Losi L; Leyvraz S; Benhattar J
    PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testis-specific transcriptional regulators selectively occupy BORIS-bound CTCF target regions in mouse male germ cells.
    Rivero-Hinojosa S; Kang S; Lobanenkov VV; Zentner GE
    Sci Rep; 2017 Feb; 7():41279. PubMed ID: 28145452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective apoptosis of breast cancer cells by siRNA targeting of BORIS.
    Dougherty CJ; Ichim TE; Liu L; Reznik G; Min WP; Ghochikyan A; Agadjanyan MG; Reznik BN
    Biochem Biophys Res Commun; 2008 May; 370(1):109-12. PubMed ID: 18355444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway.
    Yao J; Huang A; Zheng X; Liu T; Lin Z; Zhang S; Yang Q; Zhang T; Ma H
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):419-431. PubMed ID: 27838786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of BORIS/CTCFL efficiently regulates cancer stemness and metastasis in MYCN amplified neuroblastoma cell line by modulating Wnt/β-catenin signaling pathway.
    Garikapati KR; Patel N; Makani VKK; Cilamkoti P; Bhadra U; Bhadra MP
    Biochem Biophys Res Commun; 2017 Feb; 484(1):93-99. PubMed ID: 28104398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of BORIS in melanoma: lack of association with MAGE-A1 activation.
    Kholmanskikh O; Loriot A; Brasseur F; De Plaen E; De Smet C
    Int J Cancer; 2008 Feb; 122(4):777-84. PubMed ID: 17957795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy.
    Horibe R; Hirohashi Y; Asano T; Mariya T; Suzuki T; Takaya A; Saijo H; Shionoya Y; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Watanabe K; Atsuyama E; Toji S; Hirano H; Hasegawa T; Takahashi H; Sato N; Torigoe T
    PLoS One; 2017; 12(3):e0171460. PubMed ID: 28248963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BORIS in human cancers -- a review.
    Martin-Kleiner I
    Eur J Cancer; 2012 Apr; 48(6):929-35. PubMed ID: 22019212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BORIS: a key regulator of cancer stemness.
    Soltanian S; Dehghani H
    Cancer Cell Int; 2018; 18():154. PubMed ID: 30323717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of brother of the regulator of imprinted sites in peripheral blood neutrophils is associated with both benign and malignant breast lesions.
    El-Sharkawy NM; Radwan WM; Essa ES; Kandeel EZ; Abd El-Fattah EK; Kandil SH; Kamel AM
    Cytometry B Clin Cytom; 2017 Sep; 92(5):355-360. PubMed ID: 27219508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The epigenetic factor BORIS (CTCFL) controls the androgen receptor regulatory network in ovarian cancer.
    Salgado-Albarrán M; González-Barrios R; Guerra-Calderas L; Alcaraz N; Estefanía Sánchez-Correa T; Castro-Hernández C; Sánchez-Pérez Y; Aréchaga-Ocampo E; García-Carrancá A; Cantú de León D; Herrera LA; Baumbach J; Soto-Reyes E
    Oncogenesis; 2019 Aug; 8(8):41. PubMed ID: 31406110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.